Skip to content

Nevirapine use in PEP: concerns over rash

Australian HIV vaccine shows promise

Another drug bites the dust: Glaxo-Wellcome drop NNRTI

Disappointing amprenavir results: only 30% undetectable at 48 weeks

Male breast enlargement seen with all drug classes

Therapeutic drug monitoring: quality control still needed, international study shows

UK trial finds no diffference in failure rates of thicker versus standard condoms for gay men

Brazil pulls plug on HIV drugs in budget crisis

Hep C drug may increase nucleoside analogue toxicity